Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes
Open Access
- 19 December 2014
- journal article
- research article
- Published by Elsevier BV in Parkinsonism & Related Disorders
- Vol. 21 (3), 231-235
- https://doi.org/10.1016/j.parkreldis.2014.12.012
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 27 references indexed in Scilit:
- Neuropathy in Parkinson’s Disease Patients with Intestinal Levodopa Infusion versus Oral DrugsPLOS ONE, 2013
- Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim resultsParkinsonism & Related Disorders, 2013
- Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?Journal of Neural Transmission, 2013
- Epidemiology and etiology of Parkinson’s disease: a review of the evidenceEuropean Journal of Epidemiology, 2011
- Levodopa and 3-OMD levels in Parkinson patients treated with DuodopaEuropean Neuropsychopharmacology, 2010
- Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson DiseaseClinical Neuropharmacology, 2008
- Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s DiseaseNeurodegenerative Diseases, 2008
- Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson DiseaseClinical Neuropharmacology, 2008
- The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot studyMovement Disorders, 2007
- Levodopa‐induced dyskinesiasMovement Disorders, 2007